Survival and cArdiovascular eVents in Patients With Acute Myocardial Infarction (SAVING)

July 3, 2024 updated by: Jianping LI, Peking University First Hospital

Survival and cArdiovascular eVents in Patients With Acute Myocardial Infarction in Peking UNiversity First Hospital: A lonG-term Cohort Study

This prospective and prospective cohort study aims to establish a long-term follow-up cohort of patients with acute myocardial infarction, and combine multi-omics studies, wearable devices, artificial intelligence technology, etc., to describe the clinical characteristics of patients with acute myocardial infarction and the changing trend of treatment strategies, and analyze the related influencing factors. Explore new biomarkers and indicators affecting recurrent cardiovascular events for accurate risk stratification and risk prediction; To evaluate the factors affecting lifestyle intervention, drug efficacy and safety, and their impact on outcome, and improve chronic disease management mode, in order to improve the quality of life and prognosis of patients.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100034
        • Recruiting
        • Division of Cardiology, Peking University First Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients hospitalized in the department of Cardiology or outpatient department of Peking University First Hospital will be enrolled if they are aged ≥18 years old, meet the inclusion criteria of acute myocardial infarction and need long-term follow-up according to the judgment of doctors after informed consent. There are about 7500 retrospectively enrolled patients, and it is expected to enroll 500 patients per year.

Description

Inclusion Criteria:

  • Acute myocardial infarction is diagnosed meets the universal definition of acute myocardial infarction

Exclusion Criteria:

  • Did not agree to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Major Adverse Cardiovascular Events
Time Frame: 5 years
Composite end points of Cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke
5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Secondary Adverse Cardiovascular Events
Time Frame: 5 years
All-cause death, non-cardiac death, myocardial infarction, hospitalization for coronary revascularization, hospitalization for heart failure, hospitalization for acute coronary syndrome, ischemic stroke, hemorrhagic stroke
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Peking University First Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2024

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

December 31, 2028

Study Registration Dates

First Submitted

June 23, 2024

First Submitted That Met QC Criteria

July 3, 2024

First Posted (Actual)

July 5, 2024

Study Record Updates

Last Update Posted (Actual)

July 5, 2024

Last Update Submitted That Met QC Criteria

July 3, 2024

Last Verified

July 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024yan097-002

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe